Rising cardiovascular disease prevalence is a key factor supporting growth in the urokinase therapeutics landscape. Healthcare providers are emphasizing timely thrombolytic intervention to reduce complications and mortality. Continuous innovation in formulation stability is strengthening clinical reliability.             Urokinase API...